arrow
S

Shan-Liang Sun

Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization
H指数:15
被引数:728

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discovery of FYJ-195 as a Highly Potent FLT3 Inhibitor against Multiple Acquired Resistance Mutations in Acute Myeloid Leukemia

FYJ-195作为针对急性髓系白血病中多种获得性耐药突变的强效FLT3抑制剂的发现

2026-05-230
PRE
Design, Synthesis, and Biological Evaluation of 3,4-Dihydroisoquinolin-1(2H)-one Derivatives as Protein Arginine Methyltransferase 5 Inhibitors for the Treatment of Non-Hodgkin's Lymphoma
2024-12-260
PRE
Design, Synthesis, and Biological Activities Evaluation of Type I FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia
2024-11-210
PRE
Discovery of 1-(Phenylsulfonyl)-1,2,3,4-tetrahydroquinoline Derivative as Orally Bioavailable and Safe RORγt Inverse Agonists for Potential Treatment of Rheumatoid Arthritis
2024-11-150
PRE
Design and synthesis 1H-Pyrrolo[2,3-b]pyridine derivatives as FLT3 inhibitors for the treatment of Acute myeloid Leukemia

1h-吡咯并 [2,3-b] 吡啶衍生物FLT3抑制剂的设计与合成,用于治疗急性髓系白血病

2024-02-011
PRE
Preclinical characterization of danatinib as a novel FLT3 inhibitor with excellent efficacy against resistant acute myeloid leukemia

danatinib作为新型FLT3抑制剂对耐药急性髓系白血病具有优异疗效的临床前特征

2023-12-013
OAAI